Literature DB >> 15855455

Evaluating the safety of new vaccines: summary of a workshop.

Susan S Ellenberg1, Mary A Foulkes, Karen Midthun, Karen L Goldenthal.   

Abstract

Public concerns about the safety of vaccines arise on a regular basis. In November 2000, a workshop titled "Evaluation of New Vaccines: How Much Safety Data?" was convened by US Public Health Service agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, to discuss appropriate methods for evaluating the safety of new vaccines. Workshop presentations addressed the current standards and approaches for new vaccine evaluation and postlicensure surveillance, as well as public views about vaccine safety and alternative approaches that could be considered. The advantages and disadvantages of conducting large controlled trials before licensure or widespread use of a new vaccine were discussed. We summarize these presentations and discussions.

Mesh:

Substances:

Year:  2005        PMID: 15855455      PMCID: PMC1449258          DOI: 10.2105/AJPH.2004.039438

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  30 in total

1.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

Authors:  J Eskola; H Käyhty; A K Takala; H Peltola; P R Rönnberg; E Kela; E Pekkanen; P H McVerry; P H Mäkelä
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

2.  Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study.

Authors:  Z Sun; Y Zhu; J Stjernsward; M Hilleman; R Collins; Y Zhen; C C Hsia; J Lu; F Huang; Z Ni
Journal:  Cancer Detect Prev       Date:  1991

3.  The Vaccine Adverse Event Reporting System (VAERS).

Authors:  R T Chen; S C Rastogi; J R Mullen; S W Hayes; S L Cochi; J A Donlon; S G Wassilak
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

4.  Why do we need some large, simple randomized trials?

Authors:  S Yusuf; R Collins; R Peto
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

Review 5.  Smallpox vaccination reactions, prophylaxis, and therapy of complications.

Authors:  J A Goldstein; J M Neff; J M Lane; J P Koplan
Journal:  Pediatrics       Date:  1975-03       Impact factor: 7.124

Review 6.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

Authors:  P M Strebel; R W Sutter; S L Cochi; R J Biellik; E W Brink; O M Kew; M A Pallansch; W A Orenstein; A R Hinman
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

7.  The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963.

Authors:  N Nathanson; A D Langmuir
Journal:  Am J Epidemiol       Date:  1995-07-15       Impact factor: 4.897

8.  The Swedish childhood diabetes study. An analysis of the temporal variation in diabetes incidence 1978-1987.

Authors:  L Nyström; G Dahlquist; M Rewers; S Wall
Journal:  Int J Epidemiol       Date:  1990-03       Impact factor: 7.196

9.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Authors:  L Gustafsson; H O Hallander; P Olin; E Reizenstein; J Storsaeter
Journal:  N Engl J Med       Date:  1996-02-08       Impact factor: 91.245

10.  An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial.

Authors:  S M Lesko; A A Mitchell
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

View more
  11 in total

1.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

2.  What should an ideal vaccine postlicensure safety system be?

Authors:  Marie R Griffin; M Miles Braun; Kenneth J Bart
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

3.  Sequential generalized likelihood ratio tests for vaccine safety evaluation.

Authors:  Mei-Chiung Shih; Tze Leung Lai; Joseph F Heyse; Jie Chen
Journal:  Stat Med       Date:  2010-11-20       Impact factor: 2.373

4.  Rapid emergence of free-riding behavior in new pediatric immunization programs.

Authors:  Chris T Bauch; Samit Bhattacharyya; Robert F Ball
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

Review 5.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

6.  Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine.

Authors:  Huilin Ou; Wei Yao; Nanping Wu; Frederick X C Wang; Tianhao Weng; Chengcong Han; Xiangyun Lu; Dongshan Yu; Haibo Wu; Linfang Cheng; Honglin Chen; Hangping Yao; Lanjuan Li
Journal:  Oncotarget       Date:  2016-12-06

7.  Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.

Authors:  Quyen Thi Nguyen; Chaewon Kwak; Wang Sik Lee; Jaemoo Kim; Jinyoung Jeong; Moon Hee Sung; Jihyun Yang; Haryoung Poo
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

8.  Evaluating the safety of a rotavirus vaccine: the REST of the story.

Authors:  Joseph F Heyse; Barbara J Kuter; Michael J Dallas; Penny Heaton
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

9.  Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.

Authors:  Robert L Davis
Journal:  Pharmaceutics       Date:  2013-03-12       Impact factor: 6.321

10.  Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.

Authors:  Fabien V K Diomandé; Téné M Yaméogo; Kirsten S Vannice; Marie-Pierre Preziosi; Simonetta Viviani; Claude-Roger Ouandaogo; Modibo Keita; Mamoudou H Djingarey; Nehemie Mbakuliyemo; Bartholomew Dicky Akanmori; Samba O Sow; Patrick L F Zuber
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.